MyoGene Bio receives funding from CureDuchenne Ventures

May 11, 2024

CureDuchenne Ventures announced an investment in MyoGene Bio as they contribute co-funding for a California Institute for Regenerative Medicine grant awarded to the company. This allows MyoGene to further leverage non-dilutive funding to advance our cutting-edge therapy for Duchenne. We are very grateful for their support and validation! 

Read more here: 

https://cureduchenne.org/press-release/cureduchenne-ventures-invests-in-myogene-bio-and-its-aav-delivered-crispr-cas9-gene-editing-approach/